The Latest Breaking News from Takeda

QDENGA dengue vaccine to hit India market in 2027; Dr Reddy’s to sell it

India's first approved dengue vaccine, QDENGA, will launch in the private market by mid-2027. Dr Reddy's Laboratories will distribute and promote the vaccine for individuals aged four to sixty. Takeda will retain rights for public market distribution as a future objective. QDENGA is a two-dose vaccine designed to protect against…

The Economic Times · Sep 18

Once Daily Psoriasis Pill from Takeda Enters Priority FDA Review with a Decision Expected in Early 2027

Takeda's once-daily psoriasis pill zasocitinib, entered FDA Priority Review with a target decision date in the first quarter of 2027.

Medical Daily · Sep 14

A New Weekly Injection Cut Repeat Blood Draws for Most Patients with a Rare Blood Cancer

FDA approved Mimrylo for polycythemia vera. In trial data, 76.9% of patients needed no blood draws during weeks 20 to 32, versus 32.9% on placebo.

Medical Daily · Sep 1

FDA Approves First Narcolepsy Drug That Targets the Brain Signal Loss Behind the Disorder

FDA-approved Orzeyful, the first narcolepsy type 1 drug that restores orexin signaling instead of treating symptoms one at a time.

Medical Daily · Aug 7

Takeda Biopharmaceuticals gets DCGI nod for dengue vaccine QDENGA

Takeda Biopharmaceuticals India has received market authorization for its dengue vaccine QDENGA. This vaccine is now approved for individuals aged four to sixty years old. QDENGA offers protection against all four dengue virus serotypes without prior testing. The vaccine has been approved in forty-three countries since its launch. India accounts…

The Economic Times · Jul 20

Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program. The earnings call also mar

MarketBeat · May 15

5 ‘Outstanding’ Kitchen Knives That This Michelin-Starred Chef Would Actually Recommend — They “Combine Design Elegance With Exceptional Function”

"A chef's knife is the heartbeat of my kitchen," says Petros Dimas, Domes Resorts executive chef and Makris Restaurants chef patron. Here are some standouts you can count on for precision, balance, and responsiveness

Livingetc · Dec 7, 2025

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. (NYSE:TAK).

Benzinga · Oct 14, 2025

What's Going On With Takeda Stock On Friday?

On Friday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.

Benzinga · Aug 22, 2025

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase.

Benzinga · Jul 30, 2025